Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial — DUTHY

Metastatic Thyroid Cancer Clinical Trial

Official title:
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial

Status Active, not recruiting

Clinical Trial Summary

This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma
Metastatic Thyroid Cancer
Metastatic Thyroid Follicular Carcinoma
Metastatic Thyroid Papillary Carcinoma
Thyroid Cancer, Papillary
Thyroid Diseases
Thyroid Neoplasms

Clinical Trial Details

NCT number	NCT03753919
Study type	Interventional
Source	Grupo Espanol de Tumores Neuroendocrinos
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	April 2, 2019
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02390739` - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer	Phase 1/Phase 2
Recruiting	`NCT05668962` - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC	Phase 2
Recruiting	`NCT04619316` - Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition	Phase 2
Recruiting	`NCT03099356` - Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer	Phase 2